CVAC trades 350.6% below Wall Street's consensus target of $21.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CVAC achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, CureVac N.V. (CVAC) has a Wall Street consensus price target of $21.00, based on estimates from 8 covering analysts. With the stock currently trading at $4.66, this represents a potential upside of +350.6%. The company has a market capitalization of $1.05B.
Analyst price targets range from a low of $5.00 to a high of $37.00, representing a 152% spread in expectations. The median target of $21.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Hold, with 2 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 1 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, CVAC trades at a trailing P/E of 6.5x. Analysts expect EPS to grow -148.6% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $8.41, with bear and bull scenarios of $5.30 and $11.08 respectively. Model confidence stands at 41/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
MRNAModerna, Inc. | $25.4B | $63.96 | $40.29 | -37.0% | Hold | — | 27 |
BNTXBioNTech SE | $23.0B | $90.89 | $132.33 | +45.6% | Buy | — | 24 |
ARCTArcturus Therapeutics Holdings Inc. | $214M | $7.53 | $22.50 | +198.8% | Buy | — | 21 |
NTLAIntellia Therapeutics, Inc. | $1.8B | $15.67 | $26.13 | +66.8% | Buy | — | 39 |
BEAMBeam Therapeutics Inc. | $3.5B | $34.14 | $48.00 | +40.6% | Buy | — | 27 |
CRSPCRISPR Therapeutics AG | $5.2B | $54.09 | $71.67 | +32.5% | Buy | — | 38 |
IONSIonis Pharmaceuticals, Inc. | $12.2B | $74.12 | $109.44 | +47.7% | Buy | — | 32 |
ALNYAlnylam Pharmaceuticals, Inc. | $37.1B | $278.09 | $454.27 | +63.4% | Buy | 37.1x | 52 |
PFEPfizer Inc. | $143.5B | $25.22 | $26.75 | +6.1% | Hold | 8.5x | 39 |
JNJJohnson & Johnson | $550.4B | $228.39 | $251.55 | +10.1% | Buy | 19.7x | 40 |
Quick answers to the most common questions about buying CVAC stock.
The consensus Wall Street price target for CVAC is $21, representing 350.6% upside from the current price of $4.66. With 8 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
CVAC has a consensus rating of "Hold" based on 8 Wall Street analysts. The rating breakdown is mixed, with 5 Hold ratings making up the largest segment. The consensus 12-month price target of $21 implies 350.6% upside from current levels.
CVAC's current price is $4.66 with a consensus target of $21 (350.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $37 for CVAC, while the most conservative target is $5. The consensus of $21 represents the median expectation. Our quantitative valuation model projects a bull case target of $11 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
CVAC is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 5 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CVAC stock forecast based on 8 Wall Street analysts shows a consensus price target of $21, with estimates ranging from $5 (bear case) to $37 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $8, with bear/bull scenarios of $5/$11.
Our quantitative valuation model calculates CVAC's fair value at $8 (base case), with a bear case of $5 and bull case of $11. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 41/100.
Wall Street analysts are very optimistic on CVAC, with a "Hold" consensus rating and $21 price target (350.6% upside). 2 of 8 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CVAC analyst price targets range from $5 to $37, a 152% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $21 consensus represents the middle ground. Our model's $5-$11 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.